1. Published Name of the Standard for which request is being made 2. Standards Material/Document 3. Date of Request 4. Use Period 5. Reason for extension, timeline, and actions 6. Original Publication Date 7. End date of the current STU period 8. Length of the requested extension 9. Review Process 10. HL7 Work Group making this request and date 10a. Requesting WG Date 11. URL of approval minutes 12. HL7 Product Management Group 12a. Management Group Date of Approval 13. URL of approval minutes 14. Is the artifact ready for final publication? 15. If not ready, please describe remaining steps. 16. Tool name used to produce the machine processable artifacts in the IG 17. The name of the “IG artifact” within the context of the above mentioned tool. 18. Balloted Name of the standard for which request is being made 19. Requested name for published standard 20. If CMET, list IDs balloted 21. Project Insight Number 22. Document Realm 23. Ballot cycle in which the document was successfully balloted 25. Affirmative 26. Negative 27. Abstentions 28. Not Returned 29. Total in ballot pool 30. Date on which final document/standards material was supplied to HQ 31. URL of publication material/ SVN repository 32. Publishing Facilitator 33. Special Publication Instructions 34. URL of ballot reconciliation document 35. Has the Work Group posted its consideration of all comments received in its reconciliation document on the ballot desktop? 36. Substantive Changes Since Last Ballot? 37. Product Brief Reviewed By 38. Date Product Brief Reviewed 39. Has the Product Brief changed? 40. Family 41. Section 42. Topic 43. Please Describe the Topic 44. Product Type 45. Parent standard 46. Parent Standard Status 47. Update/replace standard 48. Common name/search keyword 49. Description 50. Stakeholders 51. Vendors 52. Providers 53. Benefits 54. Implementations/Case Studies 55. Development Background
HL7/NCPDP Informative Document: Pharmacist Consultation Note, Release 1- US Realm
Informative
Feb 27, 2023
Pharmacy
Feb 27, 2023
https://confluence.hl7.org/pages/viewpage.action?pageId=156545329
Yes
not applicable
not applicable
HL7/NCPDP Informative Document: Pharmacist Consultation Note, Release 1- US Realm
HL7/NCPDP Informative Document: Pharmacist Consultation Note, Release 1
1743
US Realm
2022-09
58
1
45
39
134
Feb 27, 2023
https://confluence.hl7.org/download/attachments/79512445/20230226%20Pharmacist%20Consultation%20Note%20for%20publication.docx?version=1&modificationDate=1677520664743&api=v2
Scott Robertson
http://www.hl7.org/documentcenter/public/ballots/2022SEP/reconciliation/recon_hl7_pharm_consult_r1_i1_2022sep.xls
Yes
No
Pharmacy WG
Feb 27, 2023
Cross-Paradigm
Clinical and Administrative Domains, Implementation Guides
Pharmacy
Guidance on the use of C-CDA Consultation Note and C-CDA on FHIR for a Pharmacist Consultation Note
Document
HL7 Implementation Guide for CDA® Release 2: Consolidated CDA Templates for Clinical Notes (US Realm) Standard for Trial Use Release 2.1
C-CDA on FHIR 1.1.0 - (FHIR R4) STU Release 1.1 Consultation Note Profile
Active
supplemental
pharmacy consult note, pharmacist consult note, consultant pharmacist consultation note
Health Care IT
Healthcare Institutions (hospitals, long term care, home care, mental health)